摘要
目的 :观察尿激酶静脉溶栓治疗急性心肌梗死的疗效。方法 :将 6 6例急性心肌梗塞住院患者随机分成两组 ,溶栓组 35例在常规治疗的同时 ,用尿激酶静脉溶栓治疗 ,非溶栓组仅用常规治疗 ,两组进行比较分析。结果 :溶栓组血管再通率 74 .3% ,非溶栓组为 2 5 .81 % ,两组间有明显差异 (P <0 .0 5 ) ,住院 4周的病死率 ,溶栓组为 2 .86 % ,非溶栓组为 1 6 .1 6 % ,两组间有显著差异 (P <0 .0 1 )。结论 :尿激酶静脉溶栓能明显提高急性心肌梗死患者的血管再通率和抢救成功率 。
Objectives: To observe the efficacy in patients with acute myocardial infarction treated with urokinase in vein thrombolytic therapy. Methods: Sixty-six patients with acute myocardial infarction were randomly devided into two groups,Thirty-five patients in thrombolytic group received both conventional and urokinase in vein thrombolytic therapy,and the non or thrombolytec group received only conventional work. Results: The reperfusion rare was 74.3% in the thrombolytec group compared with 25.81% in the non or thombolytic, the difference between the two group was significant (p<0.05). The fatality rate after four weeks was 2.86% in the thrombolytic group compared with 16.16% in the non or thrombolytic group.The difference is also significant (p<0.01). Conclusion: The application of urokinase in vein thrombolytic to the treatment of acute myocardial infaretion can improve the patient's reperfusion rate and success rate, reduce the fatality rate.
出处
《激光生物学报》
CAS
CSCD
2004年第4期283-285,共3页
Acta Laser Biology Sinica
关键词
急性心肌梗死
尿激酶
溶栓治疗
acute myocardial infarction
urokinase
thrombolytic therapy